Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells

Xiao,Ruo-Zhi; He,Cheng-Ming; Xiong,Mu-Jun; Ruan,Xing-Xing; Wang,Li-Lin; Chen,Yan; Lin,Dong-Jun

doi:10.3892/or.2013.2331

Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells

Authors:
- Ruo-Zhi Xiao
- Cheng-Ming He
- Mu-Jun Xiong
- Xing-Xing Ruan
- Li-Lin Wang
- Yan Chen
- Dong-Jun Lin
View Affiliations

Affiliations: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, P.R. China
Published online on: March 6, 2013 https://doi.org/10.3892/or.2013.2331
Pages: 1895-1901

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mitogen-activated protein kinase (MAPK) pathway has a protective function on the management of hematologic malignancies. The aim of this study was to assess whether the induction of MAPK-mediated effects contributes to the therapeutic value of combination sorafenib and daunorubicin (DNR) treatment. Herein, we found that DNR increased phosphorylation of extracellular signal-regulated kinases (ERK1/2) in K562 cells. ERK1/2 activity was blocked by either the mitogen-induced extracellular kinase (MEK) inhibitor U0126 or a multi-kinase inhibitor sorafenib. Of note, sorafenib sensitized K562 to DNR by inhibiting proliferation and inducing apoptosis in a dose-dependent manner which was through blocking the RAF/MEK/ERK pathway. Moreover, K562 cells transfected with a constitutively active MEK2DD plasmid showed increasing IC50 values following DNR treatment compared with control cells. Combination of DNR with MEK inhibitor U0126 synergistically inhibited K562 cell growth. In conclusion, our results indicated that sorafenib sensitized K562 cells to DNR-induced cytotoxicity by downregulating p-ERK1/2 expression. DNR in combination with sorafenib may represent a new and potential therapeutic strategy in treating acute leukemia with high p-ERK1/2 levels.

View Figures

View References

1	Thornalley PJ and Dodd NJ: Free radical production from normal and adriamycin-treated rat cardiac sarcosomes. Biochem Pharmacol. 34:669–674. 1985. View Article : Google Scholar : PubMed/NCBI
2	Pommier Y: DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol. 32:103–108. 1993. View Article : Google Scholar : PubMed/NCBI
3	Weinstein-Oppenheimer CR, Henríquez-Roldán CF, Davis JM, et al: Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res. 7:2898–2907. 2001.PubMed/NCBI
4	Kim SH, Lee SH, Kwak NH, Kang CD and Chung BS: Effects of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett. 98:199–205. 1996. View Article : Google Scholar : PubMed/NCBI
5	Cornwell MM and Smith DE: A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem. 268:15347–15350. 1993.PubMed/NCBI
6	Mas VM, Hernandez H, Plo I, et al: Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin. Blood. 101:1543–1550. 2003. View Article : Google Scholar : PubMed/NCBI
7	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
8	Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI
9	Kornblau SM, Womble M, Qiu YH, et al: Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 108:2358–2365. 2006. View Article : Google Scholar : PubMed/NCBI
10	Kolch W: Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 6:827–837. 2005. View Article : Google Scholar : PubMed/NCBI
11	Yoon S and Seger R: The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 24:21–44. 2006. View Article : Google Scholar : PubMed/NCBI
12	McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
13	Giehl K: Oncogenic Ras in tumour progression and metastasis. Biol Chem. 386:193–205. 2005. View Article : Google Scholar : PubMed/NCBI
14	Thompson N and Lyons J: Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol. 5:350–356. 2005. View Article : Google Scholar : PubMed/NCBI
15	Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
16	Strumberg D, Clark JW, Awada A, et al: Safety, pharmaco-kinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 12:426–437. 2007. View Article : Google Scholar : PubMed/NCBI
17	Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
18	Wilhelm S, Carter C, Lynch M, et al: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
19	Cummings J, Anderson L, Willmott N and Smyth JF: The molecular pharmacology of doxorubicin in vivo. Eur J Cancer. 27:532–535. 1991. View Article : Google Scholar : PubMed/NCBI
20	Quillet-Mary A, Mansat V, Duchayne E, et al: Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia. 10:417–425. 1996.PubMed/NCBI
21	Hannun YA: Functions of ceramide in coordinating cellular responses to stress. Science. 274:1855–1861. 1996. View Article : Google Scholar : PubMed/NCBI
22	Han W, Sun J, Feng L, et al: Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS One. 6:e284912011. View Article : Google Scholar : PubMed/NCBI
23	Weinstein-Oppenheimer CR, Blalock BL, Steelman LS, et al: The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor responsive tumors. Pharmacol Ther. 88:229–279. 2000. View Article : Google Scholar : PubMed/NCBI
24	Abrams SL, Steelman LS, Shelton JG, et al: The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle. 9:1781–1791. 2010. View Article : Google Scholar : PubMed/NCBI
25	Dasmahapatra G, Yerram N, Dai Y, Dent P and Grant S: Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res. 13:4280–4290. 2007. View Article : Google Scholar : PubMed/NCBI
26	Yu C, Friday BB, Lai JP, et al: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH₂-terminal kinase pathways. Mol Cancer Ther. 5:2378–2387. 2006. View Article : Google Scholar : PubMed/NCBI
27	Towatari M, Iida H, Tanimoto M, et al: Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia. 11:479–484. 1997. View Article : Google Scholar : PubMed/NCBI
28	Laurent G and Jaffrézou JP: Signaling pathways activated by daunorubicin. Blood. 98:913–924. 2001. View Article : Google Scholar : PubMed/NCBI